1-deoxynojirimycin has been researched along with Non-alcoholic Fatty Liver Disease in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Honda, Y; Imajo, K; Iwaki, M; Kessoku, T; Kobayashi, T; Nagashima, Y; Nakajima, A; Nogami, A; Ogawa, Y; Ozaki, A; Saito, S; Tomeno, W; Yoneda, M | 1 |
Kishida, Y; Ohno, H; Oki, K; Okubo, H; Yoneda, M | 1 |
Hu, B; Hu, H; Jiang, N; Liu, H; Ma, J; Yang, H; Zhang, Z; Zheng, J; Zhu, L; Zou, X | 1 |
Aerts, JM; Aten, J; Bietrix, FM; Bijl, N; Boot, RG; Dekker, N; Groen, AK; Groener, J; Langeveld, M; Lombardo, E; Ottenhoff, R; Overkleeft, HS; Serlie, M; van Eijk, M; van Roomen, C; Wennekes, T | 1 |
1 review(s) available for 1-deoxynojirimycin and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Glycosphingolipids and insulin resistance.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Fatty Acids; Fatty Liver; Gaucher Disease; Glucosyltransferases; Glycosphingolipids; Humans; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Pyrrolidines; Receptor, Insulin; Signal Transduction | 2011 |
3 other study(ies) available for 1-deoxynojirimycin and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
Topics: 1-Deoxynojirimycin; Animals; Chronic Disease; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Gastrointestinal Absorption; Gene Expression; Glucose; Insulin Resistance; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Patient Acuity; RNA, Messenger; Sodium-Glucose Transporter 1; Sorbitol | 2021 |
Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
Topics: 1-Deoxynojirimycin; Animals; Diet, High-Fat; Disease Models, Animal; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2017 |
1-Deoxynojirimycin improves high fat diet-induced nonalcoholic steatohepatitis by restoring gut dysbiosis.
Topics: 1-Deoxynojirimycin; Animals; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Glucose Intolerance; Hepatitis; Insulin; Lipids; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2019 |